Cross-source identity
National Provider Identifier 1376832196 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1376832196 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1376832196 | 28 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1376832196 | 36 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 46e15b7e… | Canonical resolved node · 4 identifier(s) · 1 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $12,963 | 6 |
| Travel and Lodging | $1,327 | 5 |
| Food and Beverage | $360 | 8 |
| Education | $64 | 6 |
| Manufacturer | Amount | Records |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | $7,539 | 9 |
| Boehringer Ingelheim International Gmbh | $4,498 | 3 |
| Pfizer Inc. | $3,200 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Gammagard Liquid(Immun Glob G(Igg)/Gly/Iga Ov50) | 20 | $216,890 |
| Dupixent Syringe(Dupilumab) | 40 | $179,921 |
| Rinvoq(Upadacitinib) | 28 | $176,185 |
| Taltz Autoinjector(Ixekizumab) | 12 | $82,659 |
| Bexarotene | 13 | $16,638 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Global Services, Llc (NJ) | cms_open_payments |
| 1 |
| Regeneron Pharmaceuticals, Inc. | $2,894 | 9 |
| Therakos Healthcare Llc | $1,300 | 1 |